Advertisement

Cutaneous Manifestations of Human Immunodeficiency Virus: a Clinical Update

  • Kirstin Altman
  • Erin Vanness
  • Ryan P. WestergaardEmail author
Skin, Soft Tissue, Bone and Joint Infectious Diseases (N Safdar, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Skin, Soft Tissue, Bone and Joint Infections

Abstract

Dermatologic diseases are common in the HIV-infected population. Many of the cutaneous diseases are not unique to this group, but the presentation can be more severe. Although the introduction of antiretroviral therapy has been followed by a decline in many of the skin diseases associated with HIV, drug reactions and other non-infectious skin conditions have increased. This article reviews the current spectrum of HIV-associated skin conditions, focusing on common complaints, infections, drug-associated toxicity and malignancies.

Keywords

HIV Cutaneous disease MRSA Polyomavirus Skin cancer SJS/TEN 

Notes

Acknowledgments

This work is supported by NIH grant K23DA032306.

Compliance with Ethics Guidelines

Conflict of Interest

We declare that we have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    UNAIDS (2012) ‘Global Report: UNAIDS Report on the Global AIDS Epidemic 2012’. http://www.avert.org/worldwide-hiv-aids-statistics.htm
  2. 2.
    CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2011. HIV Surveillance Supplemental Report 2013;18(No. 5).Google Scholar
  3. 3.
    CDC. Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012;17(No. 4).Google Scholar
  4. 4.
    Mankahla A, Mosam A. Common skin conditions in children with HIV/AIDS. Am J Clin Dermatol. 2012;13(3):153–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Cedeno-Laurent F, Gómez-Flores M, Mendez N, Ancer-Rodríguez J, Bryant JL, Gaspari AA, et al. New insights into HIV-1-primary skin disorders. J Int AIDS Soc. 2011;14:5.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Smith KJ, Skelton HG, Yeager J, Ledsky R, McCarthy W, Baxter D, et al. Cutaneous findings in HIV-1-positive patients: a 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol. 1994;31(5 Pt 1):746–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Rodgers S, Leslie KS. Skin infections in HIV-infected individuals in the era of HAART. Curr Opin Infect Dis. 2011;24(2):124–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Bolognia J, Jorizzo J, Schaffer J. Dermatology. 3rd ed. Elsevier; 2012Google Scholar
  9. 9.•
    Kaushik SB, Cerci FB, Miracle J, Pokharel A, Chen SC, Chan YH, et al. Chronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life. J Am Acad Dermatol. 2014;70(4):659–64. This cross sectional study evaluates the most common skin complaints in patients in the US and their effect on the quality of life. CrossRefPubMedGoogle Scholar
  10. 10.
    Rane SR, Agrawal PB, Kadgi NV, Jadhav MV, Puranik SC. Histopathological study of cutaneous manifestations in HIV and AIDS J Eur Acad Dermatol Venereol. 2013 Feb; 27(2).Google Scholar
  11. 11.
    Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N Engl J Med. 2001;344(1):11–6.CrossRefGoogle Scholar
  13. 13.
    Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008;29(6):510–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Popovich KJ, Weinstein RA, Aroutcheva A, Rice T, Hota B. Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis. 2010;50(7):979–87.CrossRefPubMedGoogle Scholar
  15. 15.••
    Popovich KJ, Hota B, Aroutcheva A, Kurien L, Patel J, Lyles-Banks R, et al. Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients. Clin Infect Dis. 2013;56(8):1067–74. This study shows increased MRSA colonization burden in HIV patients and highlights associated risk factors. CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Zervou FN, Zacharioudakis IM, Ziakas PD, Rich JD, Mylonakis E. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis. Clin Infect Dis. 2014;59(9):1302–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Vyas KJ, Shadyab AH, Lin CD, Crum-Cianflone NF. Trends and factors associated with initial and recurrent methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue infections among HIV-infected persons: an 18-year study. J Int Assoc Provid AIDS Care. 2014;13(3):206–13.CrossRefPubMedGoogle Scholar
  18. 18.
    Kazem S, van der Meijden E, Feltkamp MC. The trichodysplasia spinulosa-associated polyomavirus: virological background and clinical implications. APMIS. 2013;121(8):770–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Ehlers B, Wieland U. The novel human polyomaviruses HPyV6, 7, 9 and beyond. APMIS. 2013;121(8):783–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. Virology. 2013;437(2):63–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Wieland U, Silling S, Hellmich M, Potthoff A, Pfister H, Kreuter A. Human polyomaviruses 6, 7, 9, 10 and Trichodysplasia spinulosa-associated polyomavirus in HIV-infected men. J Gen Virol. 2014;95(Pt 4):928–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Rogers HD, Macgregor JL, Nord KM, Tyring S, Rady P, Engler DE, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol. 2009;60(2):315–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Vicente A, Pau-Charles I, González-Enseñat MA, Muñoz-Almagro C, Cañadas MP, Noguera-Julian A, et al. High-risk alpha-human papillomavirus types: detection in HIV-infected children with acquired epidermodysplasia verruciformis. J Am Acad Dermatol. 2013;68(2):343–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Jacobelli S, Laude H, Carlotti A, Rozenberg F, Deleuze J, Morini JP, et al. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol. 2011;147(5):590–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30(11):1011–30.CrossRefPubMedGoogle Scholar
  26. 26.
    Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schöpf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol. 1993;129(8):1059.CrossRefPubMedGoogle Scholar
  27. 27.
    Dziuban EJ, Hughey AB, Stewart DA, Blank DA, Kochelani D, Draper HR, et al. Stevens-Johnson syndrome and HIV in children in Swaziland. Pediatr Infect Dis J. 2013;32(12):1354–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Saka B, Barro-Traoré F, Atadokpédé FA, Kobangue L, Niamba PA, Adégbidi H, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):5.CrossRefGoogle Scholar
  29. 29.
    Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007.Google Scholar
  30. 30.
    Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S. Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol. 2005;35(6):1722–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Smith KJ, Skelton HG, Yeager J, Ledsky R, Ng TH, Wagner KF. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Clin Exp Dermatol. 1997;22(3):118–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Yang C, Mosam A, Mankahla A, Dlova N, Saavedra A. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4+ T cells. J Am Acad Dermatol. 2014;70(6):1096–102.CrossRefPubMedGoogle Scholar
  33. 33.
    Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006;43(1):47–55.CrossRefPubMedGoogle Scholar
  34. 34.
    Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18(17):2285–93.CrossRefPubMedGoogle Scholar
  35. 35.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.CrossRefPubMedGoogle Scholar
  36. 36.
    Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi’s sarcoma with and without visceral involvement. J Clin Oncol. 2006;24(21):3408–14.CrossRefPubMedGoogle Scholar
  37. 37.
    Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010;127(6):1437–45.CrossRefPubMedGoogle Scholar
  38. 38.
    Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103(3):416–22.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Hleyhel M, Belot A, Bouvier AM, et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2013;57(11):1638–47.CrossRefPubMedGoogle Scholar
  40. 40.
    Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc. 1997;29(1–2):828–30.CrossRefPubMedGoogle Scholar
  42. 42.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.CrossRefPubMedGoogle Scholar
  43. 43.•
    Silverberg MJ, Leyden W, Warton EM, Quesenberry Jr CP, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105(5):350–60. This is a cohort study showing a higher risk of non-melanoma skin cancer in HIV patients. CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Kirstin Altman
    • 1
  • Erin Vanness
    • 1
  • Ryan P. Westergaard
    • 2
    • 3
    Email author
  1. 1.Department of DermatologyUniversity of Wisconsin School of Medicine & Public HealthMadisonUSA
  2. 2.Departments of Medicine and Population Health SciencesUniversity of Wisconsin School of Medicine & Public HealthMadisonUSA
  3. 3.Division of Infectious DiseasesMadisonUSA

Personalised recommendations